The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings

Int J Neuropsychopharmacol. 2004 Dec;7(4):453-60. doi: 10.1017/S1461145704004687. Epub 2004 Sep 30.

Abstract

Several studies have demonstrated the involvement of 5-HT1A receptors in the pathogenesis of depression and in the antidepressant response to SSRIs. A functional new variant in the promoter region of the 5-HT1A gene was recently reported (-1019 C>G). The aim of this study is to investigate a possible association between this 5-HT1A receptor variant and antidepressant response to fluvoxamine in a sample of 262 mood-disorder subjects (151 major depressed and 111 bipolars) treated with fluvoxamine for 6 wk. The severity of depressive symptoms was assessed weekly with the Hamilton Rating Scale for Depression (HAMD). 5-HT1A variants did not influence antidepressant response in the whole sample and in unipolar subjects. In bipolars, 5-HT1A*C/C genotype carriers showed a better response to fluvoxamine (p=0.036), independently from clinical variables. The 5-HT1A polymorphism effect on antidepressant response was independent from the previously reported effect of the 5-HTTLPR polymorphism. In conclusion, 5-HT1A variants could influence the antidepressant efficacy in bipolar subjects, even if results must be verified on larger samples.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents, Second-Generation / therapeutic use*
  • DNA / genetics
  • Female
  • Fluvoxamine / therapeutic use
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Mood Disorders / drug therapy*
  • Mood Disorders / genetics*
  • Mood Disorders / psychology
  • Promoter Regions, Genetic / genetics*
  • Psychiatric Status Rating Scales
  • Receptor, Serotonin, 5-HT1A / genetics*

Substances

  • Antidepressive Agents, Second-Generation
  • Receptor, Serotonin, 5-HT1A
  • DNA
  • Fluvoxamine